Literature DB >> 2477472

Characterization of the early steps of herpes simplex virus replication in interferon-treated human cells.

F Oberman1, A Panet.   

Abstract

Interferon (IFN) was shown to inhibit herpes simplex virus type 1 (HSV-1) replication at the transcription of the immediate early (alpha) genes. This apparent inhibition could be due to a direct effect on viral transcription or on one of the preceding steps of infection, i.e., penetration and uncoating. In the present study, we analyze the effects of IFN on the very early steps of HSV-1 infection in HEp-2 human cells. Analysis of the parental HSV-1 viral DNA accumulated in the infected cell nuclei indicated that viral DNA penetration, migration to the nuclei, and stability were not affected by IFN treatment. To analyze the effect of IFN on the uncoating of the parental HSV-1 DNA following infection, we developed a technique based on DNase I sensitivity of the infecting viral DNA genome. Within 1 h of infection, the parental viral DNA became sensitive to DNase I digestion. HSV-1 DNA in the nuclei of both control and IFN-treated cells was equally sensitive to DNase I digestion, suggesting that IFN's mode of action was unrelated to the uncoating of HSV-1 virions. Because IFN does not affect the events in the HSV-1 lytic cycle prior to the onset of the immediate-early gene transcription, it appears that IFN exerts a direct effect on this process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477472     DOI: 10.1089/jir.1989.9.563

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  12 in total

1.  Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication.

Authors:  Karen L Mossman; James R Smiley
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.

Authors:  Kasey M Eidson; William E Hobbs; Brian J Manning; Paul Carlson; Neal A DeLuca
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: Potential role in blocking IFN-beta induction.

Authors:  Gregory T Melroe; Lindsey Silva; Priscilla A Schaffer; David M Knipe
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

4.  Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression.

Authors:  Dmitri G Negorev; Olga V Vladimirova; Alexey Ivanov; Frank Rauscher; Gerd G Maul
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

5.  Herpes simplex virus ICP0 mutants are hypersensitive to interferon.

Authors:  K L Mossman; H A Saffran; J R Smiley
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Specific effect of interferon on the herpes simplex virus type 1 transactivation event.

Authors:  P R De Stasio; M W Taylor
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Regulation of herpes simplex virus thymidine kinase in cells treated with a synergistic antiviral combination of alpha interferon and acyclovir.

Authors:  J L Taylor; P Tom; J Guy; R M Selvarajan; W J O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation.

Authors:  Dmitri G Negorev; Olga V Vladimirova; Gerd G Maul
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

9.  STAT-1- and IRF-3-dependent pathways are not essential for repression of ICP0-null mutant herpes simplex virus type 1 in human fibroblasts.

Authors:  Roger D Everett; Dan F Young; Rick E Randall; Anne Orr
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

10.  Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production.

Authors:  Gregory T Melroe; Neal A DeLuca; David M Knipe
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.